Dr. Hönle AG

Hönle Publishes Preliminary Figures for Financial Year 2005/2006 - Net Income Increases by 9.6 %

@@start.t1@@--------------------------------------------------------------------------------   ots.CorporateNews transmitted by euro adhoc. The issuer is responsible for   the content of this announcement. --------------------------------------------------------------------------------@@end@@

Graefeling/Munich (euro adhoc) - The UV specialist, Dr. Hönle AG (ISIN DE0005157101), published preliminary figures for financial year 2005/2006, reporting a 3.8 % rise to TEUR 23,693 in the Hönle Group sales revenues in comparison with the previous year. At the same time, earnings before interest and tax (EBIT) improved by 1.3 % to TEUR 3,473 and earnings before tax (EBT) were with TEUR 3,997 0.9 % under the previous year. Consolidated net income saw a 9.6 % rise and is now TEUR 2,742. Net profit on sales came to 11.6 % (PY: 11.0 %). The Dr. Hönle AG Supervisory Board and Board of Management will probably propose to the General Meeting that a dividend of EUR 0.30 per share be distributed from the unappropriated retained earnings of Dr. Hönle AG.

Liquid assets, financial assets and own shares amount to TEUR 19,085 (PY: TEUR 18,187), which corresponds to a cash proportion of EUR 3.51 per share.

Germany continued to be the most important sales market for Hönle and accounted for 46.8 % of total sales in comparison with 47.6 % in the previous year. At TEUR 11,081, domestic sales remained at the previous year’s level. While sales revenues earned in the European Union declined by 7.1 % to TEUR 7,269, sales figures outside Europe climbed by 29.1 % to a record high of TEUR 5,343. This jump in sales is due, in particular, to a rising demand for printing industry plants from the North-American sales region.

Outlook: The Hönle Group extended its sales team significantly in the last financial year and intensified its overall sales activities. Hönle's product range was broadened as a result of the take-over of the customer base and brand rights of Arccure Technologies GmbH, and new customers could be gained in this context. In all, Hönle expects the general conditions to be favourable and assumes positive development possibilities for the corporate group. An increase in both sales and income is expected for the new financial year.

@@start.t2@@end of announcement                                                 euro adhoc 23.11.2006 00:11:59

ots Originaltext: Dr. Hönle AG
Im Internet recherchierbar: http://www.presseportal.ch

Further inquiry note:
Peter Weinert
Tel.: +49 (0)89 856 08 173
E-Mail: peter.weinert@hoenle.de

Branche: Instrument Engineering
ISIN:      DE0005157101
WKN:        515710
Index:    CDAX, Prime All Share, Technologie All Share
Börsen:  Frankfurter Wertpapierbörse / regulated dealing/prime
              Börse Berlin-Bremen / free trade
              Hamburger Wertpapierbörse / free trade
              Baden-Württembergische Wertpapierbörse / free trade
              Börse Düsseldorf / free trade
              Niedersächsische Börse zu Hannover / free trade
              Bayerische Börse / free trade

Weitere Meldungen: Dr. Hönle AG

Das könnte Sie auch interessieren: